160 related articles for article (PubMed ID: 33369473)
21. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
22. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
24. Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.
Olde Heuvel J; de Wit-van der Veen BJ; Sinaasappel M; Slump CH; Stokkel MPM
PLoS One; 2021; 16(2):e0246394. PubMed ID: 33529259
[TBL] [Abstract][Full Text] [Related]
25. Solitary rib lesions showing prostate-specific membrane antigen (PSMA) uptake in pre-treatment staging
Chen MY; Franklin A; Yaxley J; Gianduzzo T; McBean R; Wong D; Tatkovic A; McEwan L; Walters J; Kua B
BJU Int; 2020 Sep; 126(3):396-401. PubMed ID: 32592330
[TBL] [Abstract][Full Text] [Related]
26. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
27. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
Caglar M; Tuncel M; Yildiz E; Karabulut E
Ann Nucl Med; 2020 Dec; 34(12):932-941. PubMed ID: 32975741
[TBL] [Abstract][Full Text] [Related]
28. Combination of Forced Diuresis with Additional Late Imaging in
Alberts I; Niklas-Hünermund J; Sachpekidis C; Zacho HD; Mingels C; Dijkstra L; Bohn KP; Läppchen T; Gourni E; Rominger A; Afshar-Oromieh A
J Nucl Med; 2021 Sep; 62(9):1252-1257. PubMed ID: 33547214
[TBL] [Abstract][Full Text] [Related]
29. Bony lesion analysis in carcinoma prostate: methylene diphosphonate bone scan vs. Gallium-68 psma-11 pet/ct.
Ali H; Rashid Ul Amin S; Hai A; Nizar N
J Ayub Med Coll Abbottabad; 2023; 35(3):415-418. PubMed ID: 38404083
[TBL] [Abstract][Full Text] [Related]
30. Super Early Scan of PSMA PET/CT in Evaluating Primary and Metastatic Lesions of Prostate Cancer.
Mao J; Gao M; Cui B; Zhang Y; Wang X; Liang S; Zuo C; Chen P; Dong A
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889531
[TBL] [Abstract][Full Text] [Related]
31. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
32. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
33. The influence of colour scale in lesion detection and patient-based sensitivity in [68Ga]Ga-PSMA-PET/CT.
Mingels C; Sachpekidis C; Bohn KP; Hünermund JN; Schepers R; Fech V; Prenosil G; Rominger A; Afshar-Oromieh A; Alberts I
Nucl Med Commun; 2021 May; 42(5):495-502. PubMed ID: 33481506
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
Bayerschmidt S; Uprimny C; Kroiss AS; Fritz J; Nilica B; Svirydenka H; Decristoforo C; von Guggenberg E; Horninger W; Virgolini IJ
Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34208989
[TBL] [Abstract][Full Text] [Related]
35. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer.
Lopci E; Lughezzani G; Castello A; Colombo P; Casale P; Saita A; Buffi NM; Guazzoni G; Chiti A; Lazzeri M
Clin Transl Oncol; 2021 Jan; 23(1):172-178. PubMed ID: 32447644
[TBL] [Abstract][Full Text] [Related]
36. Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.
Yin Y; Werner RA; Higuchi T; Lapa C; Pienta KJ; Pomper MG; Gorin MA; Rowe SP
J Nucl Med; 2019 Apr; 60(4):511-516. PubMed ID: 30190303
[TBL] [Abstract][Full Text] [Related]
37. Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.
van Leeuwen PJ; Emmett L; Ho B; Delprado W; Ting F; Nguyen Q; Stricker PD
BJU Int; 2017 Feb; 119(2):209-215. PubMed ID: 27207581
[TBL] [Abstract][Full Text] [Related]
38. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.
Demirci E; Sahin OE; Ocak M; Akovali B; Nematyazar J; Kabasakal L
Nucl Med Commun; 2016 Nov; 37(11):1169-79. PubMed ID: 27333090
[TBL] [Abstract][Full Text] [Related]
39. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
40. The role of (
Yilmaz U; Komek H; Can C; Altindag S
Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
